Cost-effectiveness of vaccination against pneumococcal pneumonia in The Netherlands

European Journal of Public Health

Volumn 7, Issue 2, 1997, Pages 153-161

  Baltussen, R M P M ^a   Ament, A J H A ^a   Leidl, R M ^a,b   Van Furth, R ^c  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF ULM   (Germany)

^c LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Cost effectiveness; Decision tree; Economic evaluation; Pneumococcal pneumonia; Vaccine

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DECISION THEORY; DRUG EFFICACY; ERYTHEMA; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HOSPITAL ADMISSION; HUMAN; INJECTION PAIN; LOBAR PNEUMONIA; MAJOR CLINICAL STUDY; NETHERLANDS; PREVALENCE; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; VACCINATION; WORLD HEALTH ORGANIZATION;

EID: 0030991841     PISSN: 11011262     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurpub/7.2.153     Document Type: Article

References (51)

1. Fedson D, Henrichsen J, Mäkelä PH, Austrian R. WHO recommendations on pneumococcal vaccination: immunization of elderly people with polyvalent pneumococcal vaccine. Infection 1989;17:437-41.
2. Bruyn GAW, van Furth R. Pneumococcal polysaccharide vaccines: indications, efficacy and recommendations. Eur J Clin Microbiol Infect Dis 1991;10:897-910.
3. SIG Zorginformatie. Landelijke Medische Registratie 1994 (National Medical Registration 1994). Utrecht: SIG Cooperatie UA, 1994.
4. Bohte R, van Furth R, van den Broek PJ. Aetiology of community-acquired pneumonia: a prospective study among adults requiring admission to hospital. Thorax 1995;50:543-7.
5. Sisk JE, Riegelman RK. Cost effectiveness of vaccination against pneumococcal pneumonia: an update. Ann Int Med 1986;104:79-86.
6. Mooney G. Key issues in health economics. Hemel Hempstead: Harvester Wheatsheaf, 1994.
7. Ministerie van Financiën, Studiegroep Discontering. De rol van de disconteringsvoet in het beleid: eindrapport (The role of the discount rate in policy-making: final report). Den Haag: Ministry of Finance, 1985.
8. Hager HL, Woolley TW, Berk SL. Review of recent pneumococcal infections with attention to vaccine and nonvaccine serotypes. Rev Infect Dis 1990;12:267-72.
9. Fedson DS. Clinical practice and public policy for influenza and pneumococcal vaccination of the elderly. Clin Geriat Med 1992;8:183-99.
10. Fiebach N, Beckett W. Prevention of respiratory infections in adults: influenza and pneumococcal vaccines. Arch Int Med 1994;154:2545-57.
11. Hirschmann JV, Lipsky BA. The pneumococcal vaccine after 15 years of use. Arch Int Med 1994;154:373-7.
12. Austrian R, Gold J. Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Arch Dis Child 1964;60:759-76.
13. Simberkoff MS, Cross AP, Al-lbrahim M, et al. Efficacy of pneumococcal vaccine in high-risk patients. New Engl J Med 1986;315:1318-31.
14. Forrester HL, Jahnigen DW, LaForce FM. Inefficacy of pneumococcal vaccine in a high-risk population. Am J Med 1987;83:425-30.
15. Fine MJ, Smith MA, Carson CA, et al. Efficacy of pneumococcal vaccination in adults: a meta-analysis of randomized controlled trials. Arch Int Med 1994;154:2666-77.
16. Shapiro ED, Clemens JD. A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infection. Ann Int Med 1984;101:325-30.
17. Sims RV, Steinmann WC, McConville JH, King LR, Zwick WC, Schwartz JS. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Int Med 1988;108:653-7.
18. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharides vaccine. New Eng J Med 1991;325:1453-60.
19. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy: an evaluation of current recommendations. JAMA 1993;270:1826-31.
20. Bentley DW. Vaccinations. Clin Geriat Med 1992;8:745-60.
21. Simberkoff MS. Pneumococcal vaccine in the prevention of community-acquired pneumonia: a sceptical view of cost-effectiveness. Sem Respirat Infect 1993;8:294-9.
22. Gable CB, Holzer SS, Engelhart L, et al. Pneumococcal vaccine: efficacy and associated cost savings. JAMA 1990;264:2910-5.
23. van der Velden J, de Bakker DH, Claessens AAMC, Schellevis FG. Een nationale Studie naar ziekten en verrichtingen in de huisartspraktijk. Basisrapport: morbiditeit in de huisartsenpraktijk (A national study on diseases and procedures in general practice). Utrecht: Nederlands Instituut voor onderzoek van de eerstelijnsgezondheidszorg (NIVEL), 1991.
24. Morbidity and Mortality Weekly Report Centres for Disease Control. Recommendations of the immunization practices advisory committee pneumococcal polysaccharides vaccine. JAMA 1989;261:1265-7.
25. Bartlett JG, Mundy LM. Community-acquired pneumonia. New Engl J Med 1995;14:1618-24.
26. Ortqvist A, Hedlund J, Grillner L, et al. Aetiology, outcome and prognostic factors in community-acquired pneumonia requiring hospitalization. Eur Respirat J 1990;3:1105-13.
27. Karalus NC, Cursons RT, Leng RA, et al. Community-acquired pneumonia: aetiology and prognostic index evaluation. Thorax 1991;46:413-8.
28. Research Committee of the British Thoracic Society and the Public Health Laboratory Service. Community-acquired pneumonia in adults in British hospitals in 1982-1983: a survey of aetiology, mortality, prognostic factors and outcome. Q J Med New Series 1987;62:195-220.
29. Centraal Bureau voor de Statistiek (CBS). Overleden naar doodsoorzaak (Mortality statistics by cause). Voorburg: CBS, Afdeling Doodsoorzaken, 1994.
30. Centraal Bureau voor de Statistiek (CBS). Overlevingstafels naar leefijd en geslacht (Life tables by age and sex). Voorburg: CBS, Hoofdafdeling Bevolkingsstatistieken, 1992.
31. Beck JR, Pauker SG, Gottlieb JE, Klein K, Kassirer JP. A convenient approximation of life expectancy (the 'DEALE'): II. Use in medical decision-making. Am J Med 1982;73:889-97.
32. Lew EA, Gajewski J. Medical risks: patterns of mortality by age and time elapsed. New York: Praeger, 1990.
33. Centraal Bureau voor de Statistiek (CBS). Statistisch bulletin 46. Voorburg: Centraal Bureau voor de Statistiek, 1995.
34. Van de Kuy A, editor. Farmacotherapeutisch Kompas 1995: medische farmaceutische voorlichting (Medical farmaceutical counseling). Amstelveen: Centrale Medisch Pharmaceutische Commissie van de Ziekenfondsraad, 1982.
35. Stuurgroep Toekomstscenario's Gezondheidszorg (STG). Kostenberekening bij gezondheidszorgonderzoek (Cost assessment at health care research). Rijswijk: STG, 1993.
36. de Koning H, van Ineveld BM, van Oostmarssen GJ, et al. Breast cancer screening and cost-effectiveness: policy alternatives, quality of life considerations and the possible impact of uncertain factors. Int J Cancer 1991;49:531-7.
37. Koopmanschap MA, Lubbe KT, van Oortmarssen GJ, van Agt HM, van Ballegooijen M, Habbema JK. Economic aspects of cervical cancer screening. Soc Sci Med 1990;30:1081-7.
38. Austrian R. Pneumococcal pneumonia: diagnostics, epidemiologic, therapeutic and prophylactic considerations. Chest 1986;90:738-43.
39. Centraal Medische Registratie Nijmegen (CMR-Nijmegen). Hospital referral rates for pneumonia 1990-1994. Nijmegen: Katholieke Unjversiteit, Department of General Practice and Social Medicine, 1995
40. Lamberts H. In het huis van de huisarts: verslag van het Transitieproject (At home by the general practitioner: report from the Transition project). Lelystad: Meditekst, 1991.
41. Chang JI, Mylotte JM. Pneumococcal bacteremia: update from an adult hospital with a high rate of nosocomial cases. J Am Geriat Soc 1987;35:747-54.
42. Bruyn GAW, Kremer HPH, de Marie S, Padberg GW, Hermans J, van Furth R. Clinical evaluation of pneumococcal meningitis in adults over a twelve-year period. Eur J Clin Microbiol Infect Dis 1989;8:695-700.
43. Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions. JAMA 1989;262:907-13.
44. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature. Ann Int Med 1995;123:518-27.
45. Hofmann J, Cetron MS, Farley MM, et al. The prevalence of drug-resistant streptococcus pneumoniae in Atlanta. New Engl J Med 1995;333:481-6.
46. Kamlett MS. The comparative benefits modelling project: a framework for cost-utility analysis of government health care programs. Washington: US Department of Health and Human Services, Public Health Service, Office of Disease Prevention and Health Promotion, 1992.
47. Organisation for Economic Co-operation and Development (OECD). OECD health systems: fact and trends 1960-1991. Paris: OECD, 1993.
48. Huber M, Kose A, Schneider M. Wirtschaftlichkeit und Leistungsniveau deutscher Krankenhauser im internationalen Vergleich (The performance of German hospitals in international comparison). Augsburg: BASYS, 1993.
49. Willems JS, Sanders CR, Riddiough MA, Bell JR. Cost-effectiveness of vaccination against pneumococcal pneumonia. New Engl J Med 1980;303:553-9.
50. Plans P, Garrido P, Salleras L. Coste-effectivedad de la vacunación pneumocócica. Rev Esp Salud Pública 1995;69:409-17.
51. Tugwell P, Bennett KJ, Sackett DL, Haynes RB. The measurement iterative loop: a framework for the critical appraisal of need, benefits and costs of health interventions. J Chronic Dis 1985;38:339-51.